```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1653HXP

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *  Welcome to STN International  * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  AUG 09   INSPEC enhanced with 1898-1968 archive
 NEWS  4  AUG 28   ADISCTI Reloaded and Enhanced
 NEWS  5  AUG 30   CA(SM)/CAplus(SM) Austrian patent law changes
 NEWS  6  SEP 11   CA/CAplus enhanced with more pre-1907 records
 NEWS  7  SEP 21   CA/CAplus fields enhanced with simultaneous left and right
                   truncation
 NEWS  8  SEP 25   CA(SM)/CAplus(SM) display of CA Lexicon enhanced
 NEWS  9  SEP 25   CAS REGISTRY(SM) no longer includes Concord 3D coordinates
 NEWS 10  SEP 25   CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
 NEWS 11  SEP 28   CEABA-VTB classification code fields reloaded with new
                   classification scheme
 NEWS 12  OCT 19   LOGOFF HOLD duration extended to 120 minutes
 NEWS 13  OCT 19   E-mail format enhanced
 NEWS 14  OCT 23   Option to turn off MARPAT highlighting enhancements available
 NEWS 15  OCT 23   CAS Registry Number crossover limit increased to 300,000 in
                   multiple databases
 NEWS 16  OCT 23   The Derwent World Patents Index suite of databases on STN
                   has been enhanced and reloaded
 NEWS 17  OCT 30   CHEMLIST enhanced with new search and display field
 NEWS 18  NOV 03   JAPIO enhanced with IPC 8 features and functionality
 NEWS 19  NOV 10   CA/CAplus F-Term thesaurus enhanced
 NEWS 20  NOV 10   STN Express with Discover! free maintenance release Version
                   8.01c now available

 NEWS EXPRESS  NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:59:02 ON 11 NOV 2006
```

```
=> file medline, biosis, uspatful, dgene
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.42       0.42

FILE 'MEDLINE' ENTERED AT 14:59:55 ON 11 NOV 2006

FILE 'BIOSIS' ENTERED AT 14:59:55 ON 11 NOV 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'USPATFULL' ENTERED AT 14:59:55 ON 11 NOV 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 14:59:55 ON 11 NOV 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

=> s (alpha-antiplasmin)
L1          44 (ALPHA-ANTIPLASMIN)

=> s l1 and cleaving enzyme
L2           0 L1 AND CLEAVING ENZYME

=> s (alpha-antiplasmin cleaving enzyme)
L3           0 (ALPHA-ANTIPLASMIN CLEAVING ENZYME)

=> s l1 and (alpha-2)
L4          21 L1 AND (ALPHA-2)

=> s l4 and (cleavage)
L5           6 L4 AND (CLEAVAGE)

=> d l5 ti abs ibib tot

L5   ANSWER 1 OF 6  BIOSIS  COPYRIGHT (c) 2006 The Thomson Corporation  on STN
TI   Regulation of fibrinolysis by non-esterified fatty acids.
AB   The ability of oleic acid to modulate fibrinolysis was measured by
     following the urokinase-mediated and plasminogen-dependent
     cleavage of 125I-labelled fibrin clots.  Oleic acid levels within
     the physiological range exerted a concentration-dependent inhibition of
     urokinase-mediated fibrinolytic activity.  SDS/PAGE revealed that oleic
     acid enhances urokinase activity but simultaneously increases the
     autolytic cleavage of the newly formed low-molecular-mass
     subunit of plasmin.  Oleic acid-induced cleavage of this subunit
     containing the catalytic site of plasmin was suppressed by the plasmin
     substrate H-D-valyl-L-leucyl-L-lysine-p-nitroanilide (S-2251) and was
     prevented by alpha-2-antiplasmin.  A
     concentration-dependent inhibition of the activity of purified plasmin on
     125I-labelled fibrin clot was also observed; 93% and 50% inhibition was
     noted with 150 mu-M and 32 mu-M oleic acid respectively.  Oleic acid at
     200 mu-M also effectively displaced plasmin prebound to a
     polylysine-Sepharose column.  Examination of the fatty acid specificity
     showed that a minimal chain length of 16 carbon atoms and the presence of
     at least one double bond, preferably in a cis configuration, were required
     for inhibition of the fibrinolytic activity of plasmin.  Oleic acid at a
     concentration that produced only a minimal inhibition of plasmin activity
     induced a marked inhibition by palmitic acid, while palmitic acid alone is
     ineffective.  The findings suggest that oleic acid stimulates plasminogen
     activation and modulates the fibrinolytic and autolytic activities of
     plasmin.
ACCESSION NUMBER:    1994:310531  BIOSIS
DOCUMENT NUMBER:     PREV199497323531
TITLE:               Regulation of fibrinolysis by non-esterified fatty acids.
```

AUTHOR(S): Higazi, Abd Al-Roof [Reprint author]; Aziza, Rifat; Samara, Abd Al-Ruhman; Mayer, Michael
CORPORATE SOURCE: Dep. Clin. Biochem., Hadassah Med. Cent., P.O. Box 12000, Jerusalem, IL 91120, Israel
SOURCE: Biochemical Journal, (1994) Vol. 300, No. 1, pp. 251-255. ISSN: 0264-6021.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 26 Jul 1994
Last Updated on STN: 27 Jul 1994

L5 ANSWER 2 OF 6 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI RELEASE OF B-BETA PEPTIDES FROM FIBRINOGEN OR FIBRIN IN THE PRESENCE OF ALPHA ANTIPLASMIN.
AB When Glu-plasminogen (plg) was activated by urokinase (UK) in the presence of fibrinogen or fibrin, Bβ peptides (Bβ 1-42) were released faster from fibrinogen than from fibrin(Bβ 15-42). These results were contrary to faster release of Bβ 15-42 from fibrin in the UK-activated clotted plasma in comparison to the release of Bβ 1-42 from UK-activated plasma. The addition of plasma or lysine-Sepharose pass through fraction to the above system resulted in faster release of Bβ peptides from fibrin than fibrinogen. The addition of .alpha. 2 antiplasmin (α2AP) to the mixture of Glu-plg, UK and fibrinogen or fibrin resulted in faster release of Bβ peptides from fibrin than from fibrinogen. These results indicate that fibrin protected plasmin from inactivation by α2AP, leading to cleavage of Arg(42)-Ala(43) bond in β-chain of fibrin which seems to be less susceptible to plasmin than the same bond in fibrinogen.
ACCESSION NUMBER: 1986:255632 BIOSIS
DOCUMENT NUMBER: PREV198682010381; BA82:10381
TITLE: RELEASE OF B-BETA PEPTIDES FROM FIBRINOGEN OR FIBRIN IN THE PRESENCE OF ALPHA ANTIPLASMIN.
AUTHOR(S): TAKADA A [Reprint author]; MAKINO Y; TAKADA Y
CORPORATE SOURCE: DEP PHYSIOLOGY, HAMAMATSU UNIV, SCH MED, HAMAMATSU-SHI, SHIZUOKA-KEN, JPN
SOURCE: Thrombosis Research, (1986) Vol. 42, No. 1, pp. 1-10. CODEN: THBRAA. ISSN: 0049-3848.
DOCUMENT TYPE: Article
FILE SEGMENT: BA
LANGUAGE: ENGLISH
ENTRY DATE: Entered STN: 21 Jun 1986
Last Updated on STN: 21 Jun 1986

L5 ANSWER 3 OF 6 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI EFFECTS OF HUMAN GRANULOCYTE ELASTASE ON FIBRINOLYSIS.
AB The specific limited proteolysis of human plasminogen by human granulocyte elastase results in the cleavage of 3 peptides from the H chain of plasminogen. These 3 peptides bind to lysine- and fibrin-Sepharose. The remainder of the molecule possesses a MW of 38,000 and represents a fully activatable plasminogen lacking the lysine binding site(s) in the H chain. Upon treatment of this low MW form of plasminogen with urokinase, esterolytic, fibrinolytic and amidolytic activities appear. The low MW form of plasmin consists of 2 S-S-linked polypeptide chains with MW .apprx. 25,000 and 13,000. The kinetic parameters of hydrolysis of synthetic substrates by the low MW form of plasmin and native plasmin, respectively, are similar. The inhibitions of the 2 enzymes by several inhibitors of the hydrolysis of Blue Dextran-fixed fibrin are identical. The initial rate of activation with urokinase is .apprx. 2 times faster for the low MW form of plasminogen than for native plasminogen, and the activation of native plasminogen by urokinase in inhibited by plasma . alpha.2-antiplasmin, whereas the activation of the low MW form of plasminogen is not. Urokinase-induced clot lysis is inhibited efficiently by .alpha.2-antiplasmin, but the

inhibitory effect of .alpha.-antiplasmin is removed by H chain fragments containing lysine binding site(s), which are obtainable from plasminogen by limited elastase digestion. Urokinase-induced fibrinolytic activity of plasma is promoted by human granulocyte elastase in an apparently time-dependent manner. Apparently, lysine binding site(s) in the H chain of plasmin(ogen) are of great importance in relation to the rate of its reaction with .alpha.2-antiplasmin.

ACCESSION NUMBER: 1982:147824 BIOSIS
DOCUMENT NUMBER: PREV198273007808; BA73:7808
TITLE: EFFECTS OF HUMAN GRANULOCYTE ELASTASE ON FIBRINOLYSIS.
AUTHOR(S): NAGAMATSU A [Reprint author]; SOEDA S
CORPORATE SOURCE: FACULTY OF PHARMACEUTICAL SCIENCES, FUKUOKA UNIV, NANAKUMA, NISHI-KU, FUKUOKA, 814-01, JAPAN
SOURCE: Chemical and Pharmaceutical Bulletin (Tokyo), (1981) Vol. 29, No. 4, pp. 1121-1129.
CODEN: CPBTAL. ISSN: 0009-2363.
DOCUMENT TYPE: Article
FILE SEGMENT: BA
LANGUAGE: ENGLISH

L5 ANSWER 4 OF 6 USPATFULL on STN
TI Compositions and methods for treating thrombotic disorders
AB The invention provides compositions containing a chimeric microplasmin polypeptide and methods for fibrinolytic therapy using the chimeric polypeptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:299248 USPATFULL
TITLE: Compositions and methods for treating thrombotic disorders
INVENTOR(S): Reed, Guy L., Boston, MA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004235115	A1	20041125	
APPLICATION INFO.:	US 2003-715981	A1	20031118	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-427152P	20021118	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL CENTER, BOSTON, MA, 02111
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 1041
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 6 USPATFULL on STN
TI Yeast expression vector and a method of making a recombinant protein by expression in a yeast cell
AB Vectors for the expression in yeast of mammalian plasminogen derivatives such as microplasminogen and miniplasminogen are presented. Methods for expression of these proteins in a methylotrophic yeast expression system are disclosed as well as the activation and stabilisation of the recombinant proteins. The proteins of this invention are used In the treatment of focal cerebral ischemic infarction and other thrombotic diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:94224 USPATFULL
TITLE: Yeast expression vector and a method of making a recombinant protein by expression in a yeast cell
INVENTOR(S): Collen, Desire Jose, London, UNITED KINGDOM
Nagai, Nubuo, Leuven, BELGIUM
Laroche, Yves, Brussel, BELGIUM

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004071676	A1	20040415	
APPLICATION INFO.:	US 2003-450976	A1	20031208	(10)
	WO 2001-BE217		20011220	

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-31196	20001221
	GB 2001-16690	20010709
	GB 2001-16702	20010709

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110
NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 1656
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 6 USPATFULL on STN
TI Methods of inhibiting the activation of Factor XIII
AB Compositions and methods for inhibiting the activation and/or active state of a precursor protein are provided. Compositions provided can bind to a cleavage site of a precursor protein. Also provided are compounds useful for generating inhibitor compositions. Application of the invention to the treatment of myocardial infarction and other thrombotic conditions is specifically provided. Further provided are antibodies specific for active Factor XIII.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 97:31410 USPATFULL
TITLE: Methods of inhibiting the activation of Factor XIII
INVENTOR(S): Reed, Guy L., Winchester, MA, United States
Matsueda, Gary R., Princeton, NJ, United States
Haber, Edgar, Salisbury, NH, United States
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)
General Hospital Corporation, The, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5620688		19970415	
	WO 9215609		19920917	
APPLICATION INFO.:	US 1994-117052		19940504	(8)
	WO 1992-US1926		19920311	
			19940504	PCT 371 date
			19940504	PCT 102(e) date

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1991-667296, filed on 11 Mar 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Chan, Christina Y.
ASSISTANT EXAMINER: Gambel, Phillip

LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox P.L.L.C.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 1599
CAS INDEXING IS AVAILABLE FOR THIS PATENT.